Skip to main content
. 2019 May 1;26(5):432–441. doi: 10.5551/jat.45989

Table 1. Baseline characteristics in reference to on-treatment level of LDL cholesterol and Hs-CRP.

Characteristic LDL cholesterol
P value CRP
P value
< 120 mg/dL > 120 mg/dL < 1 mg/L > 1 mg/L
(N = 591) (N = 486) (N = 732) (N = 345)
Age, years 66.8 ± 8.5 65.7 ± 8.4 0.040 66.0 ± 8.6 67.0 ± 8.1 0.084
Male, N (%) 416 (70.4) 323 (66.5) 0.188 474 (64.8) 265 (76.8) < .0001
BMI, kg/m2 23.60 ± 3.10 23.82 ± 2.92 0.241 23.48 ± 3.01 24.15 ± 3.00 0.001
Interval between index Stroke and enrollment, Months 9.52 ± 9.83 9.60 ± 10.50 0.905 9.81 ± 10.21 9.01 ± 9.98 0.223
Total cholesterol, mg/dl 202.0 ± 23.1 219.4 ± 24.4 < .0001 210.0 ± 24.9 209.5 ± 26.0 0.743
HDL cholesterol, mg/dl 55.2 ± 17.7 50.3 ± 11.8 < .0001 54.9 ± 16.2 48.9 ± 12.9 < .0001
Triglyceride, mg/dl 141.5 ± 83.4 145.3 ± 68.9 0.417 134.7 ± 67.7 161.3 ± 91.6 < .0001
Hypertension, N (%) 458 (77.5) 367 (75.5) 0.489 543 (74.2) 282 (81.7) 0.008
    Systolic blood pressure, mmHg 137.2 ± 17.8 135.8 ± 17.5 0.178 136.6 ± 17.5 136.6 ± 18.1 0.994
    Diastolic blood pressure, mmHg 79.3 ± 11.5 79.2 ± 11.1 0.827 79.3 ± 11.3 79.0 ± 11.6 0.663
Diabetes mellitus, N (%) 151 (25.5) 101 (20.8) 0.077 173 (23.6) 79 (22.9) 0.850
    Fasting blood glucose, mg/dl 121.8 ± 47.3 113.1 ± 35.7 0.001 116.9 ± 43.5 120.0 ± 40.9 0.257
Coronary artery disease, N (%) 29 (4.9) 25 (5.1) 0.968 37 (5.1) 17 (4.9) 1.000
Chronic kidney disease, N (%) 150 (25.4) 116 (23.9) 0.616 165 (22.5) 101 (29.3) 0.021
    Creatinine, mg/dl 0.806 ± 0.202 0.800 ± 0.219 0.631 0.784 ± 0.198 0.844 ± 0.228 < .0001
Smoker, N (%) 326 (55.2) 251 (51.6) 0.270 355 (48.5) 222 (64.3) < .0001
Use of antiplatelet agents, N (%) 545 (92.2) 440 (90.5) 0.383 674 (92.1) 311 (90.1) 0.347
Use of statin, N (%) 388 (65.7) 148 (30.5) < .0001 375 (51.2) 161 (46.7) 0.183
Ischemic stroke subtype
    Atherothrombotic infarction, N (%) 154 (26.1) 121 (24.9) 0.507 181 (24.7) 94 (27.2) 0.215
    Lacunar infarction, N (%) 369 (62.4) 318 (65.4) 479 (65.4) 208 (60.3)
    Undetermined etiology, N (%) 68 (11.5) 47 (9.7) 72 (9.8) 43 (12.5)
LDL cholesterol, mg/dL
    Baseline 118.9 ± 22.5 143.2 ± 20.4 < .0001 129.2 ± 24.6 131.4 ± 24.9 0.164
    On-treatment 101.7 ± 12.9 136.5 ± 13.2 < .0001 116.5 ± 21.7 119.2 ± 21.4 0.058
CRP, Median, mg/L (IQR)
    Baseline 0.636 (0.344–1.470) 0.755 (0.369–1.690) 0.041 0.488 (0.256–0.769) 1.940 (1.240–4.110) < .0001
    On-treatment 0.599 (0.327–1.130) 0.711 (0.387–1.395) 0.008 0.448 (0.261–0.659) 1.820 (1.310–2.860) < .0001

The categorical data are compared by chi-square test and the numerical data are compared by non-paired t-test, and Wilcoxon two-sample test for Hs-CRP. TIA: transient ischemic attack, BMI: body mass index, HDL: high density lipoprotein, LDL: low density lipoprotein, Hs-CRP: high-sensitivity C reactive protein, IQR: interquartile range